Background: In the realm of employee healthcare benefits, few situations present as complex and morally challenging as the case of a dedicated, long-serving employee diagnosed with Hepatitis C. The treatment option, Sovaldi, stood as a beacon of hope, offering a potential cure. However, the drug came with an exorbitant price tag of $88,000 for a three-month course, not covered by the group health insurance plan.